Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Single-Arm, Open-Label Study to Evaluate Safety, Tolerability, and Efficacy of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy in India

NCT07004972 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT07004972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07004972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Single-Arm, Open-Label Study to Evaluate Safety, Tolerability, and Efficacy of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy in India
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 4
Overall status
Active, not recruiting
Start date
September 4, 2025
Completion date
December 13, 2027
Enrollment
50 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

symptomatic obstructive hypertrophic cardiomyopathy